Introduction
============

Lung adenocarcinoma subtypes, including lepidic, papillary, acinar, solid, micropapillary, and mucinous predominant, have been defined by the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) international histological classification. Epidermal growth factor receptor (EGFR) mutations easily occur in lung adenocarcinoma patients, especially in females and non-smokers. The rates of EGFR mutations in lung adenocarcinoma in People's Republic of China are higher than those of Caucasian populations.[@b1-ott-10-3345]--[@b3-ott-10-3345] EGFR-tyrosine kinase inhibitors are considered the first-line therapeutics for lung adenocarcinoma harboring EGFR mutations.[@b4-ott-10-3345],[@b5-ott-10-3345] Anaplastic lymphoma kinase (ALK) fusion protein is present in about 5% of lung adenocarcinoma cases.[@b6-ott-10-3345],[@b7-ott-10-3345] ALK inhibitors are superior to chemotherapy in lung adenocarcinoma patients with ALK rearrangement, improving symptoms and quality of life.[@b8-ott-10-3345]--[@b10-ott-10-3345] A higher intracranial disease control rate in patients with brain metastasis was also demonstrated for ALK inhibitors compared with chemotherapy.[@b11-ott-10-3345],[@b12-ott-10-3345] Both *EGFR* and *ALK* are the main driving genes in lung adenocarcinoma.

Serum carcinoembryonic antigen (CEA) levels are usually elevated in lung adenocarcinoma patients, constituting an effective and noninvasive method for the diagnosis of this malignancy.[@b13-ott-10-3345],[@b14-ott-10-3345] CEA levels are independently associated with *EGFR* gene mutations, and the frequency of *ALK* fusion gene among patients with a serum CEA concentration below 5 ng/mL seems to be higher than that of patients with a concentration above 5 ng/mL (*P*=0.021).[@b15-ott-10-3345] CEA levels in patients with EGFR mutations and ALK fusion protein might be different from those of cases with no EGFR mutation or ALK fusion protein. As the lung cancer research field is rapidly evolving, molecular pathology attracts increasing attention. Meanwhile, information regarding the clinical characteristics and molecular pathology of lung adenocarcinoma subtypes as defined by the new IASLC/ATS/ERS classification remains limited. There may be also differences in CEA levels among the histologic subtypes of lung adenocarcinoma.

This study aimed to further assess the associations of CEA levels with histologic subtype, and the status of EGFR mutations and ALK fusion protein. A total of 442 patients were assessed, and clinicopathological parameters, serum CEA levels, and the status of EGFR mutations and ALK fusion protein were analyzed.

Methods
=======

Patients and eligibility criteria
---------------------------------

A total of 442 cases with completely resected lung adenocarcinoma (184 males and 258 females), treated from January 2014 to December 2015 in Zhejiang Cancer Hospital, People's Republic of China, were retrospectively assessed.

Inclusion criteria were stage IA--IIIA completely resected lung adenocarcinoma and 18 years of age or older. Patients were excluded from the study for any of the following reasons: 1) history of other malignancy (unless more than 5 years of disease-free state), except completely resected non-melanoma skin cancer; 2) preoperative anticancer therapy, eg, radiotherapy and chemotherapy; 3) preoperative CEA not detected; and 4) no EGFR and ALK detection after operation.

Patient characteristics
-----------------------

Median age was 61 years (range, 30--81 years). Of the 442 patients, 331, 42, 34, and 54 were non-smokers, light smokers, moderate smokers, and heavy smokers, respectively. Lung adenocarcinoma patients were divided (as proposed by the seventh edition of the TNM classification for lung cancer) as follows: 140 cases with stage IA, 140 with stage IB, 41 with stage IIA, 15 with stage IIB, and 96 with stage IIIA. In detail, 119 cases with T1a, 70 with T1b, 210 with T2a, 21 with T2b, 16 cases with T3, and 15 with T4 disease stage were included. Meanwhile, there were 311 cases with N0, 41 with N1, and 90 with N2. In the patients, preoperative CEA levels detected by chemiluminescent microparticle immunoassay (ARCHITECT i4000 chemiluminescence analyzer; Abbott, Chicago, IL, USA), EGFR mutation status assessed by amplification refractory mutation system (ARMS), and ALK fusion protein detected by Ventana (D5F3) immunohistochemistry assay (Ventana Medical Systems; Roche, Inc., Tucson, AZ, USA) were retrospectively evaluated. The current retrospective study was approved by the Medical Ethics Review Committee of Zhejiang Cancer Hospital, and exemption from written informed consent was also approved by the Medical Ethics Committee of Zhejiang Cancer Hospital. Most of the patients in this retrospective study signed the written informed consent before surgery to preserve their specimens in the Biological Sample Bank of Zhejiang Cancer Hospital to be used in research.

CEA detection
-------------

Blood samples were collected before surgery, and CEA amounts were analyzed in the clinical laboratory of our hospital.

EGFR mutation and ALK fusion detection
--------------------------------------

Pathological tissues were sent to the Department of Pathology after surgery, EGFR mutation was detected by using ARMS and ALK fusion was detected by using Ventana immunohistochemistry according to routine method.[@b16-ott-10-3345],[@b17-ott-10-3345]

Statistical analyses
--------------------

The SPSS software version 15.0 (Chicago, IL, USA) was used for all analyses. Data were assessed by the chi-square test, with *P*\<0.05 considered statistically significant. A regression hazards model was used for univariate and multivariate analyses to assess the prognostic value of preoperative serum CEA levels.

Results
=======

Serum carcinoembryonic antigen levels and lung adenocarcinoma histologic subtypes
---------------------------------------------------------------------------------

Median serum CEA levels were 2.47 ng/mL, ranging from \<0.5 to 623.54 ng/mL. Meanwhile, 310 patients had serum CEA concentrations below 5 ng/mL, and 132 patients had levels above 5 ng/mL.

All cases were invasive adenocarcinoma, including 82 lepidic (18.6%), 68 papillary (15.4%), 233 acinar (52.7%), 43 solid (9.7%), 14 micropapillary (3.2%), and two mucinous predominant (0.4%) subtypes.

Furthermore, the correlation between serum CEA levels and the histologic subtype was analyzed. There were significant differences in histologic subtype between the CEA \>5 ng/mL and CEA ≤5 ng/mL groups (*P*=0.000) ([Table 1](#t1-ott-10-3345){ref-type="table"}). Precisely, CEA levels in patients with the solid subtype were higher than those of other histologic subtypes. Meanwhile, more cases with the lepidic subtype were found in the CEA ≤5 ng/mL group compared with the CEA \>5 ng/mL group ([Table 1](#t1-ott-10-3345){ref-type="table"}).

EGFR mutations and ALK fusion protein in lung adenocarcinoma specimens
----------------------------------------------------------------------

EGFR mutations were found in 309 cases, with a mutation rate of 69.9% (309/442). Among the patients, 135 had EGFR exon 19 mutations, 153 showed EGFR exon 21 mutations, and 26 had rare EGFR mutations. Meanwhile, ALK fusion was observed in 20 cases (4.5%).

The associations of clinical features with EGFR mutations in patients with lung adenocarcinoma were analyzed ([Table 2](#t2-ott-10-3345){ref-type="table"}). EGFR mutations occurred more frequently in patients with IA, N0, lepidic subtype, and without ALK fusion protein (*P*\<0.000).

Serum CEA levels and EGFR mutations/ALK fusion protein
------------------------------------------------------

Higher preoperative serum CEA levels (CEA \>20 ng/mL) were independently associated with EGFR mutations (*P*\<0.001). In patients with CEA levels of 21--49 ng/mL, the EGFR mutation rate was 88.2%, which was higher compared with those obtained in cases with CEA levels of \<5 ng/mL, 6--19 ng/mL, and ≥50 ng/mL.

The EGFR 19 mutation incidence rate in patients with CEA levels of 21--49 ng/mL was the highest. However, the incidence rates of EGFR 21 mutations in all CEA level groups were similar ([Table 3](#t3-ott-10-3345){ref-type="table"}).

Although the incidence of ALK fusion in patients with CEA levels ≥50 ng/mL was the highest, the sample was too small.

Serum CEA levels (\>20 ng/mL) and clinicopathologic characteristics
-------------------------------------------------------------------

As CEA levels (CEA \>20 ng/mL) were independently associated with EGFR mutations, clinicopathologic characteristics between the CEA \>20 ng/mL and CEA ≤20 ng/mL groups were analyzed.

Univariate analysis showed that in addition to EGFR mutations, T and N stage and ALK fusion protein status were related to CEA levels ([Table 4](#t4-ott-10-3345){ref-type="table"}). Multivariate analysis is summarized in [Table 5](#t5-ott-10-3345){ref-type="table"}; EGFR mutations and T stage were independent risk factors for CEA.

Discussion
==========

Serum CEA levels are a critical factor in predicting the efficacy of targeted therapy and chemotherapy, as well as postoperative recurrence and metastasis. However, the associations of CEA with histologic subtype, and EGFR mutations with ALK fusion gene in patients with completely resected lung adenocarcinoma remain unknown. The current study found that preoperative serum CEA levels can serve as a reference marker to identify the histologic subtype and EGFR mutation or ALK fusion protein status in lung adenocarcinoma patients.

High serum CEA is considered to be associated with more aggressive biologic features, suggesting that serum CEA levels before surgery are related to the pathological type. As already shown, serum CEA levels differed among the histologic subtypes of lung adenocarcinoma. Specifically, CEA levels in patients with the solid subtype were higher than those of other histologic subtypes. These data indicated that the solid subtype (with higher CEA levels) might show poorer prognosis than the other histologic subtypes. The EGFR mutation status and CEA expression levels play important roles in the complex network of signal transduction pathways that regulate cell apoptosis. CEA is an adhesion protein whose expression can be activated and adjusted by EGFR signaling, which may be one of the reasons why CEA expression appears to be upregulated following EGFR mutation.[@b18-ott-10-3345] A high prevalence of EGFR mutations was found in the current study population (69.9%); previous studies reported that pure or mixed ground-glass opacity and the lepidic dominant histologic subtype could be good predictors of EGFR mutation in lung adenocarcinoma.[@b19-ott-10-3345] In this study, we showed that EGFR mutations occurred more frequently in patients with IA, N0, and the lepidic subtype. This might be because lepidic dominant lung adenocarcinoma has low incidence of lymphatic vessel invasion.[@b20-ott-10-3345]

Serum CEA levels can clearly and consistently be considered to be normal or abnormal with a set cutoff value. Several studies have revealed the prognostic value of preoperative serum CEA levels. Consistently, in this study, serum CEA expression levels were positively correlated with EGFR mutations; indeed, EGFR mutation occurrence rates increased with serum CEA levels, corroborating findings by Cai.[@b21-ott-10-3345] Hence, the EGFR mutation profile can be preliminarily forecasted using preoperative CEA levels. Serum CEA \>20 ng/mL predicted an elevation of EGFR mutation rate; the reason might be that activation of molecules downstream of EGFR mutant promotes anti-apoptosis, while CEA expression is enhanced by EGFR.

It was reported that ALK defines specific molecular subsets of lung adenocarcinomas with distinct clinical features. In the present study, high preoperative serum CEA levels (CEA \>20 ng/mL) were independently associated with ALK fusion protein expression; however, the sample size was relatively small, and large sample trials are required for confirmation.

Furthermore, clinicopathologic characteristics between the CEA \>20 ng/mL and CEA ≤20 ng/mL groups were analyzed; interestingly, EGFR mutation and T stage were independent risk factors for high CEA levels.

Tomita et al[@b22-ott-10-3345] demonstrated that lower CEA levels result in higher 5-year disease-specific survival, whereas Maeda et al[@b23-ott-10-3345] considered CEA level an important clinical predictor of tumor invasiveness and lymph node metastasis. In future studies, the association of CEA expression with the prognosis of patients with lung adenocarcinoma will be evaluated.

Conclusion
==========

Preoperative serum CEA levels have certain value for predicting the histologic subtype, as well as EGFR mutation or ALK fusion protein status, in lung adenocarcinoma patients. Moreover, histological subtypes could also predict EGFR mutations.
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###### 

Correlation between serum CEA level and lung adenocarcinoma histologic subtype

  ----------------------------------------------------------------------------------------
  Histologic subtype     n=442   CEA \>5 ng/mL\   CEA ≤5 ng/mL\   *P*-value   Chi-square
                                 (n=132)          (n=310)                     
  ---------------------- ------- ---------------- --------------- ----------- ------------
  Acinar                 233     78 (59%)         155 (50%)       0.000       24.223

  Lepidic                82      10 (7.6%)        72 (23.2%)                  

  Papillary              68      18 (13.6%)       50 (16.1%)                  

  Micropapillary         14      3 (2.3%)         11 (3.5%)                   

  Solid                  43      22 (16.7%)       21 (6.8%)                   

  Mucinous predominant   2       1 (0.8%)         1 (0.3%)                    
  ----------------------------------------------------------------------------------------

**Abbreviation:** CEA, carcinoembryonic antigen.

###### 

Clinical features in patients with lung adenocarcinoma with or without EGFR mutations

  --------------------------------------------------------------------------------------------------
  Variables                    n=442   EGFR mutation\   No EGFR mutation\   *P*-value   Chi-square
                                       (n=309)          (n=133)                         
  ---------------------------- ------- ---------------- ------------------- ----------- ------------
  Sex                                                                       0.121       2.402

   Male                        184     136              48                              

   Female                      258     173              85                              

  Age (years)                                                               0.330       0.951

   \<65                        308     211              97                              

   ≥65                         134     98               36                              

  Smoking status                                                            0.328       0.956

   No smoking                  311     212              99                              

   Light smoking (≤20)         42      31               11                              

   Moderate smoking (21--39)   35      27               8                               

   Heavy smoking (≥40)         54      39               15                              

  T                                                                         0.239       1.388

   T1a                         119     93               26                              

   T1b                         70      53               17                              

   T2a                         210     136              74                              

   T2b                         21      12               9                               

   T3                          16      10               6                               

   T4                          5       4                1                               

  N                                                                         0.000       26.080

   N0                          310     230              80                              

   N1                          41      25               16                              

   N2                          90      53               37                              

  Stage                                                                     0.000       26.968

   IA                          150     120              30                              

   IB                          140     100              40                              

   IIA                         41      21               20                              

   IIB                         15      10               5                               

   IIIA                        96      68               38                              

  Histologic subtype                                                        0.000       36.223

   Acinar                      233     170              53                              

   Lepidic                     82      68               14                              

   Papillary                   68      49               19                              

   Micropapillary              14      8                6                               

   Solid                       43      15               28                              

   Mucinous predominant        2       0                2                               

  ALK fusion                   20      2                18                  0.000       35.741
  --------------------------------------------------------------------------------------------------

**Abbreviations:** EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; T, tumor; N, lymph node.

###### 

Serum CEA level and EGFR mutation/ALK fusion

  CEA (ng/mL)   n     EGFR mutation, n (%)   EGFR 19 mutation (n=135), n (%)   EGFR 21 L858R mutation (n=153), n (%)   EGFR rare mutation, n (%)   ALK refusion (n=20), n (%)
  ------------- ----- ---------------------- --------------------------------- --------------------------------------- --------------------------- ----------------------------
  \<5           310   221 (71.3)             100 (32.3)                        105 (33.9)                              17 (5.5)                    15 (4.8)
  ≥5            132   88 (66.7)              36 (27.3)                         48 (36.4)                               4 (3.0)                     5 (3.8)
  6--19         97    62 (63.9)              23 (23.7)                         35 (36.1)                               4 (4.1)                     3 (3.1)
  ≥20           35    26 (74.3)              13 (37.1)                         13 (37.1)                               0                           2 (5.7)
  21--49        17    15 (88.2)              9 (52.9)                          6 (35.3)                                0                           0
  ≥50           18    11 (61.1)              4 (22.22)                         7 (38.9)                                0                           2 (11.1)

**Abbreviations:** CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.

###### 

Clinicopathologic characteristics of lung cancer patients with CEA \>20 ng/mL and CEA ≤20 ng/mL

  ------------------------------------------------------------------------------------------------
  Variables                    n=442   CEA \>20 ng/mL\   CEA ≤20 ng/mL\   *P*-value   Chi-square
                                       (n=35)            (n=407)                      
  ---------------------------- ------- ----------------- ---------------- ----------- ------------
  Sex                                                                     0.861       0.042

   Male                        184     14                170                          

   Female                      258     21                237                          

  Age (years)                                                             0.702       0.283

   \<65                        308     23                285                          

   ≥65                         134     12                122                          

  Smoking status                                                          0.510       0.736

   No smoking                  311     23                288                          

   Light smoking (≤20)         42      3                 39                           

   Moderate smoking (21--39)   35      2                 33                           

   Heavy smoking (≥40)         54      7                 47                           

  T                                                                       0.001       16.007

   T1a                         119     2                 117                          

   T1b                         70      2                 68                           

   T2a                         210     21                189                          

   T2b                         21      5                 16                           

   T3                          16      4                 12                           

   T4                          5       1                 4                            

  N                                                                       0.019       5.824

   N0                          310     12                298                          

   N1                          41      7                 34                           

   N2                          90      16                74                           

  Stage                                                                   0.002       10.441

   IA                          150     2                 148                          

   IB                          140     5                 135                          

   IIA                         41      8                 33                           

   IIB                         15      2                 13                           

   IIIA                        96      18                78                           

  Histologic subtype                                                      0.114       2.971

   Acinar                      233     24                209                          

   Lepidic                     82      1                 81                           

   Papillary                   68      2                 66                           

   Micropapillary              14      0                 14                           

   Solid                       43      8                 35                           

   Mucinous predominant        2       0                 2                            

  EGFR mutation                309     26                283              0.000       147.228

   EGFR 19 mutation            135     13                122              0.375       3.117

   EGFR 21 mutation            153     13                140                          

   Rare mutation               26      0                 26                           

  ALK fusion                   20      2                 18               0.000       414.711
  ------------------------------------------------------------------------------------------------

**Abbreviations:** CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; T, tumor; N, lymph node.

###### 

Multivariate analysis of relationship between CEA (cutoff 20 ng/mL) and clinicopathologic characteristics in lung cancer patients

  Variables            *P*-value   Risk ratio   95% CI for risk ratio   
  -------------------- ----------- ------------ ----------------------- --------
  Sex                  0.400       1.675        0.504                   5.569
  Age                  0.245       1.632        0.715                   3.724
  Smoking status       0.679       0.629        0.070                   5.643
  Stage                0.304       1.953        0.545                   6.998
  T                    0.029       1.670        1.053                   2.647
  N                    0.591       1.375        0.431                   4.386
  Histologic subtype   0.503       0.910        0.691                   1.199
  EGFR mutation        0.033       5.559        1.148                   26.924
  ALK fusion           0.323       2.389        0.424                   13.448

**Abbreviations:** CEA, carcinoembryonic antigen; CI, confidence interval; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; T, tumor; N, lymph node.
